BioMarin Pharmaceutical

Biomarin
Pharma

BioMarin halts dosing, enrollment in 3 midstage Voxzogo studies

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—approved for a form of dwarfism—across three indications.
Fraiser Kansteiner Mar 16, 2026 11:26am
Traffic light go start restart green light

FDA approves Ascendis' achondroplasia treatment Yuviwel

Mar 2, 2026 9:25am
Lifeline
Favicon Fierce Biotech

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm
Biomarin

BioMarin pulls gene therapy Roctavian off the market

Feb 24, 2026 12:30pm
A chessboard with blocks that read MA

BioMarin makes its largest transaction, paying $4.8B for Amicus

Dec 19, 2025 11:28am
Car reaches the end of the road

BioMarin looks to drop hemophilia gene therapy Roctavian

Oct 28, 2025 11:49am